Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Intensive therapy of older AML

Thorsten Braun • 29 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia

Thorsten Braun, MD, PhD, Hôpitaux de Paris, Université Paris 13, Bobigny, France, discusses current intensive therapy of older acute myeloid leukemia (AML) patients. Analysis of AML gene mutations can improve treatment stratification of patients who may benefit from intensive therapy and allogeneic transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thorsten Braun

1:24
Leukemia treatment in times of COVID-19
Thorsten Braun • 29 Jun 2020
2:14
Update on the AML treatment landscape
Thorsten Braun • 29 Jun 2020

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
2:04
Increasing awareness of germline predispositions to hematological malignancies in pediatric patients
Anupama Rao • 29 Apr 2024
0:57
The development of a UK AML registry
Priyanka Mehta • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals